tiprankstipranks
Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments
PremiumRatingsEntrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments
18d ago
Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials
Premium
Ratings
Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials
18d ago
Entrada Therapeutics Receives FDA Approval for DMD Study
Premium
Company Announcements
Entrada Therapeutics Receives FDA Approval for DMD Study
19d ago
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating
PremiumThe FlyRoth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating
3M ago
Entrada Therapeutics initiated with a Buy at Roth MKM
Premium
The Fly
Entrada Therapeutics initiated with a Buy at Roth MKM
3M ago
Entrada Therapeutics price target raised to $28 from $25 at Oppenheimer
Premium
The Fly
Entrada Therapeutics price target raised to $28 from $25 at Oppenheimer
4M ago
Entrada Therapeutics presents new data on expanding Duchenne Franchise
PremiumThe FlyEntrada Therapeutics presents new data on expanding Duchenne Franchise
5M ago
Entrada promotes Sethuraman to President of Research, Development
Premium
The Fly
Entrada promotes Sethuraman to President of Research, Development
6M ago
Entrada Therapeutics reports Q2 EPS $1.55, consensus 14c
Premium
The Fly
Entrada Therapeutics reports Q2 EPS $1.55, consensus 14c
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100